Aptevo Therapeutics (APVO) Cash & Current Investments (2016 - 2023)
Historic Cash & Current Investments for Aptevo Therapeutics (APVO) over the last 9 years, with Q3 2023 value amounting to $19.1 million.
- Aptevo Therapeutics' Cash & Current Investments fell 1535.63% to $19.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was $19.1 million, marking a year-over-year decrease of 1535.63%. This contributed to the annual value of $22.6 million for FY2022, which is 5111.55% down from last year.
- Aptevo Therapeutics' Cash & Current Investments amounted to $19.1 million in Q3 2023, which was down 1535.63% from $21.0 million recorded in Q2 2023.
- In the past 5 years, Aptevo Therapeutics' Cash & Current Investments registered a high of $62.9 million during Q2 2021, and its lowest value of $9.5 million during Q2 2020.
- Moreover, its 5-year median value for Cash & Current Investments was $27.5 million (2020), whereas its average is $31.9 million.
- Its Cash & Current Investments has fluctuated over the past 5 years, first tumbled by 7242.85% in 2020, then surged by 56496.14% in 2021.
- Over the past 5 years, Aptevo Therapeutics' Cash & Current Investments (Quarter) stood at $19.9 million in 2019, then surged by 126.06% to $45.1 million in 2020, then increased by 2.69% to $46.3 million in 2021, then tumbled by 51.12% to $22.6 million in 2022, then fell by 15.57% to $19.1 million in 2023.
- Its Cash & Current Investments stands at $19.1 million for Q3 2023, versus $21.0 million for Q2 2023 and $25.3 million for Q1 2023.